Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC

The advent of tyrosine kinase inhibitors (TKIs) for treating epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) has been a game changer in lung cancer therapy. However, patients often develop resistance to the drugs within a few years. Despite numerous studies that ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Keigo, Tan, Aaron C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964908/
https://www.ncbi.nlm.nih.gov/pubmed/36835536
http://dx.doi.org/10.3390/ijms24044126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964908/
https://www.ncbi.nlm.nih.gov/pubmed/36835536
http://dx.doi.org/10.3390/ijms24044126

Ejemplares similares